Intensive efforts to improve artificial pancreas technology continue apace even as Medtronic plc prepares to launch the first FDA-approved iteration by this summer. The National Institutes of Health (NIH) is highlighting four pivotal trials that it's funding, which are slated to start over the next few years. Two of the trials involve Medtronic: one for a next-generation iteration from the Dublin, Ireland-based company and the other using existing Medtronic insulin pump/continuous glucose monitor (CGM) equipment in combination with a novel algorithm. Another of the NIH-backed pivotal artificial pancreas trials relies upon an assemblage of software...
Intensive efforts to improve artificial pancreas technology continue apace even as Medtronic plc prepares to launch the first FDA-approved iteration by this summer. The National Institutes of Health (NIH) is highlighting four pivotal trials that it's funding, which are slated to start over the next few years.